Belfast, UK. 7th January, 2019.

CV6 Therapeutics Inc., a drug development company focussed on the development and commercialisation of novel combination therapeutics for cancer and inflammatory diseases, today announced that it will be featured as a presenting company at Biotech Showcase™ 2019, to be held on the 7th-9th January at the Hilton San Francisco Union Square. Dr Robert Ladner,  CEO and Founder of CV6 Therapeutics Inc., will present at the following time and location:

Date: Wednesday, January 9, 2019
Time: 13:45 (PST)
Venue: Hilton San Francisco Union Square Hotel, San Francisco, CA, USA.
Room: Yosemite A, Ballroom Level

Dr Ladner will present details of the clinical development strategy for CV6-168, a new anticancer therapeutic that is rationally-designed to significantly enhance the anticancer activity of thymidylate synthase (TS) inhibitors which are among the most widely prescribed cancer therapeutics in the world. CV6-168 has completed all preclinical development and is poised to enter first-in-human trials in 2019. CV6 Therapeutics are currently seeking Series C financing for the forthcoming Phase 1a/1b clinical trial.

“We are excited that CV6 is presenting at Biotech Showcase” said CV6 CEO Robert Ladner. “2019 will be an exciting year for CV6 as our first clinical candidate, CV6-168 enters first-in-human clinical trials. CV6-168 is the most advanced therapeutic in our innovative pipeline and represents an exciting opportunity to significantly improve treatment options for patients across multiple cancer indications, including some of the most difficult-to-treat cancers that currently lack effective therapies.”

Biotech Showcase™ is an annual investor and networking conference that provides private and public biotechnology and life science companies with an opportunity to present and meet with investors and pharmaceutical executives.

CV6 Therapeutics

CV6 Therapeutics is a drug development company focused on the discovery, development and commercialization of novel therapies for the treatment of human diseases. To learn more about CV6 Therapeutics and its product pipeline including CV6-168, or to contact us, click here: CV6 Therapeutics.